StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$520.66−15.79 (-2.94%)

Close on Nov 19, 2026Market cap $131.97BP/E 30.3Yield –

Vertex Pharmaceuticals JOURNAVX (suzetrigine) — Net product revenues by Quarter

JOURNAVX (suzetrigine) — Net product revenues ($M) ($M)

Vertex Pharmaceuticals JOURNAVX (suzetrigine) — Net product revenues: $49.6M in Q2 2026, up 313.3% from a year earlier. That is the highest of the 9 quarters on record here.

Latest, Q2 2026
49.6
Period ended Jun 30, 2026
Change on a year earlier
+313.3%
12 in Q2 2025
History
9 quarters
Since Q2 2024
Sources
5
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Revenue Disaggregation Note & Form 8-K.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedJOURNAVX (suzetrigine) — Net product revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202649.6+313.3%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 202629+2,130.8%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 202526.7–Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 202519.6–Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 202512–Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 31, 20251.30–Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 20240–Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 20240–Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2025-08-05) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals JOURNAVX (suzetrigine) — Net product revenues ($M), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-journavx

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?